Crossmark

MCM6 indicates adverse tumor features and poor outcomes and promotes G1/S cell cycle progression in neuroblastoma

Published Online: 2021-07-07

Published Print: 2021-12

Authors

Gu, Yaoyao

Hu, Xiaoxiao

Liu, Xiaowei

Cheng, Cheng

Chen, Kai

Wu, Yeming

Wu, Zhixiang https://orcid.org/0000-0002-3947-2035
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81874234)

Suzhou Clinical Medicine Innovation Team Introduction Project (SZYJTD201706)

Shanghai Sailing Program (20YF1430300)
License Information

Text and Data Mining valid from 2021-07-07

Version of Record valid from 2021-07-07
More Information

Article History

Received: 5 November 2020

Accepted: 11 May 2021

First Online: 7 July 2021

Declarations

:

: The study protocol has been approved by the ethics committee of Xinhua Hospital, and the written informed consent of the participants’ parents or guardians has been obtained.The procedures for care and use of animals were approved by the Ethics Committee of Xinhua Hospital and all applicable institutional and governmental regulations concerning the ethical use of animals were followed.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current